arrow
D

Diane Reidy-Lagunes

medicine
H指数:50
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dual pancreatic carcinomas: clonally related or independent primaries?

双发性胰腺癌:克隆相关还是独立原发灶?

2026-02-080
OAAI
Safety and efficacy of Yttrium-90 transarterial radioembolization of neuroendocrine liver metastasis – A retrospective single-institution study

钇-90经动脉放射性栓塞术治疗神经内分泌肿瘤肝转移的安全性与有效性——一项回顾性单中心研究

2025-11-250
PRE
ASO Visual Abstract: Adjuvant Cytotoxic Chemotherapy May Not Be Associated with a Survival Advantage for Resected Intrahepatic Cholangiocarcinoma
2025-01-280
PRE
Adjuvant Cytotoxic Chemotherapy may not be Associated with a Survival Advantage for Resected Intrahepatic Cholangiocarcinoma
2025-01-181
PRE
Long-term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy
2024-09-271
PRE
Dual primary pancreas cancers - Related or independent lesions?
2024-01-160
PRE
Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade
2023-10-165
PRE
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting

2021国家癌症研究所神经内分泌肿瘤临床试验计划会议共识报告

2023-05-311
OA
Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas
2023-05-194
PRE
COMPOSE: Pivotal phase III trial to compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumours

COMPOSE: 关键的III期试验,比较177Lu-edotreotide与最佳护理标准对分化良好的侵袭性2级和3级胃肠胰腺神经内分泌肿瘤

2022-09-011
OAAI
Treatment Response and Clinical Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors to Lutetium-177-DOTATATE

高分化高级别神经内分泌肿瘤对Lutetium-177-DOTATATE的治疗反应和临床结局

2022-05-2410
OA